Abstract 487P
Background
The United States Preventive Services Task Force (USPSTF) recommends low dose CT screening for lung cancer in individuals (1) 50-80 years old, (2) currently smoking or had quit for less than 15 years and (3) had at least a 20 pack-year smoking history. It is unclear if these guidelines will be applicable to our mixed Asian population. Our aim is to evaluate the performance of the USPSTF lung cancer screening criteria in our population of lung cancer patients.
Methods
We retrospectively reviewed the records of all asymptomatic patients who underwent resection of primary lung cancer in our institution between 2019 and 2021. Data collected included demographics, smoking status, histology and the final staging.
Results
We reviewed 259 consecutive cases of resectable primary lung cancer patients between 2019 and 2021. 145 patients were males (56.0%) and 114 patients were females (44.0%). There were 123 (47.5%) active or former smokers and 136 (52.5%) non-smokers. 83 patients (32.0%) met the USPSTF screening criteria and 176 patients (68.0%) did not. Lowering the age criteria to 45 years old increased the pickup rate to 34.4%. Male patients were more likely to meet the criteria (OR 2.27, 95% CI 1.87-2.76, p < 0.001) than female patients. The pickup rate increased significantly to 40.5% when patients who had stopped smoking for more than 15 years were included (p < 0.001) and 44.4% (p < 0.001) when patients who smoked less than 20 pack years were included. Screening by age criteria alone resulted in a pickup rate of 93.8% (males 94.5%, females 93.0%). Within this age range, the pickup rate in females was 84.2% in non-smokers and 8.8% in active or former smokers whilst the pickup rate in male was 22.1% in non-smokers and 72.4% in active or former smokers.
Conclusions
Our study showed the performance of the USPSTF criteria when applied to a mixed Asian population. It is concerning that more than two-thirds of patients will miss the opportunity for early curative resection if the guidelines were followed. A significant proportion of our patients were non-smokers, especially in the female population. A lung screening programme will need to be refined from existing guidelines to fit our local mixed Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract